Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
ISIS 2302 is an antisense oligonucleotide drug that reduces the production of a specific
protein called intercellular adhesion molecule (ICAM-1), a substance that plays a significant
role in the increase of inflammation. People with Crohn's disease have been shown to
over-produce ICAM-1 in their gut tissues. Alicaforsen works by blocking ICAM-1 messenger RNA,
the "instruction" molecule that is required for the production of ICAM-1 protein. This trial
will examine effects of alicaforsen delivered by 2-hour intravenous infusion over a four-week
period, compared to a placebo. Patients may remain on stable background 5-ASA, antibiotic, or
immunosuppressive drugs, and prednisone (or equivalent) at Phase:
Phase 3